Sonnet BioTherapeutics Says Early Safety Data From Phase 1b/2a Clinical Trial Of SON-080 In Chemotherapy-Induced Peripheral Neuropathy Met Study's Initial Pre-Specified Objective
Sonnet BioTherapeutics 表示,來自化療誘發的周圍神經病變的 SON-080 1b/2a 期臨床試驗的早期安全數據符合研究最初的預先設定目標